

Donor 4157

Genetic Testing Summary

Fairfax Cryobank recommends reviewing this genetic testing summary with your healthcare provider to determine suitability.

Last Updated: 04/03/23

Donor Reported Ancestry: Persian

Jewish Ancestry: No

Genetic Test*	Result	Comments/Donor's Residual Risk**

Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/ and a-/a-) and other hemoglobinopathies
Cystic Fibrosis (CF) carrier screening	Negative by genotyping of 97 mutations in the CFTR gene	1/160
Spinal Muscular Atrophy (SMA) carrier screening	Negative for deletions of exon 7 in the SMN1 gene	1/628
Tay Sachs enzyme analysis	Non-carrier by Hexosaminidase A activity	
Special Testing		
Gene: DHCR7	Negative by gene sequencing	See attached result.

*No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.

**Donor residual risk is the chance the donor is still a carrier after testing negative.



Celebrating 25 Years of Excellence

Cytogenetic Report

Client						
Reporting Phone #		Fax #		Em	ail N/A	
Patient name/Donor Alia	s Donor 4157			Patient DOB	N/A	
Donor #	¢ 4157			Specimen type	Periphera	al Blood
Collection Date	e 10/05/2009			Accession #	09-055C	G
Date Received	10/06/2009					
		RESU	LTS			
СҮТО	GENETIC A	NALYSIS			FISH	ľ
Cells counted	20	Type of banding	GTG		Probe(s)	N/A
Cells analyzed	5	Band resolution	500	Nuc	elei scored	N/A
Cells karyotyped	2					
Modal chromosome #	46					
KARYOTYPE 46.XY						

INTERPRETATION

Normal male karyotype

No numerical or structural abnormalities were identified. This normal cytogenetic result does not exclude the possibility of the presence of subtle rearrangements beyond the technical limits of detection with this test.

Comments

ገግል Wayne S. Stanley, Ph.D., FACMG **Clinical Cytogeneticist**


10/15/09 Date

Genetics and IVF Preimplantation Genetics Laboratory


Patient name: Donor # 4157

Case name: 09-055CG

46,XY



Case: 09-055CG	Slide: A1	Cell: 20





Cystic Fibrusis Mutation Analysis

Patient Name: Donor # 415 Referring Physician: Specimen #: Patient ID:	Client #:	
DOB: Not Given Sex: M SSN:	Date Collected: 09/11/2009 Date Received: 09/12/2009 Lab ID: 4157090911 Hospital ID: Specimen Type: BLDPER	

Ethnicity: Asian

Indication: Carrier test / Gamete donor

RESULTS: Negative for the 97 mutations analyzed

INTERPRETATION

This individual is negative for the mutations analyzed. This result reduces but does not eliminate the risk to be a CF carrier.

COMMENTS:

Mutation Detection Rates Detection rates are based on mutation frequencies in patients affected with cystic fibrosis. Among individuals with an atypical or mild presentation (e.g. congenital absence of the vas deferens, pancreatitis) detection rates may vary from those provided here.				
Ethnicity	Carrier risk reduction when no family history	Detection rate	References	
African American	1/65 to 1/338	81%	Genet in Med 3:168, 2001	
Ashkenazi Jewish	1/26 to 1/834	97%	Am J Hum Genet 51:951, 1994	
Asian		Not Provided	Insufficient data	
Caucasian	1/25 to 1/343	93%	Genet in Med 3:168, 2001; Genet in Med 4:90, 2002	
Hispanic	1/46 to 1/205	78%	Genet in Med 3:168, 2001;www.dhs.ca.gov/pcfh/gdb/html/PDE/CFStudy.htm	
Jewish, non-Ashkenazi		Varies by country of origin	Genet Testing 5:47, 2001, Genet Testing, 1:35, 1997	
Other or Mixed Ethnicity		Not Provided	Detection rate not determined and varies with ethnicity	

This interpretation is based on the clinical and family relationship information provided and the current understanding of the molecular genetics of this condition.

METHOD

DNA is isolated from the sample and tested for the 97 CF mutations listed. Regions of the *CFTR* gene are amplified enzymatically and subjected to a solution-phase multiplex allele-specific primer extension with subsequent hybridization to a bead array and fluorescent detection. The assay discriminates between Δ F508 and the following polymorphisms: F508C, I506V and I507V. In some cases, specific allele identification requires enzymatic amplification followed by hybridization to oligonucleotide probes.

Under the direction of:



Narasimhan Nagan, Ph.D., FACMG

Date: 09/18/2009

Page 1 of 1

Testing Performed At Genzyme Genetics 3400 Computer Drive Westborough, MA 01581 1-800-255-7357

zyme

SMN1 Copy (mber Analysis

Patient Name: . Donor # 4157		
DOB:	Age:	606452 / 348795
SSN #:	Gender: Male	
Genzyme Specimen #:61376321-6		
Case #:	Patient ID #	
Date Collected: 09/11/2009	Date Received: 09/12/2009	
Referring Physician:		Client Lab ID #:
Genetic Counselor:		Hospital ID #:
		Specimen ID #:
Specimen Type: Peripheral Blood	1	Specimen(s) Received: 2 - Yellow (ACD) 10 ml round bottom tube(s)
Clinical Data: Carrier Test/Gamete	donor	Ethnicity: Asian

RESULTS: SMN1 copy number: 2 (Reduced Carrier Risk)

INTERPRETATION:

This individual has an SMN1 copy number of two. This result reduces but does not eliminate the risk to be a carrier of SMA. Ethnic specific risk reductions based on a negative family history and an SMN1 copy number of two are provided in the Comments section of this report.

COMMENT:

Spinal muscular atrophy (SMA) is an autosomal recessive disease of variable age of onset and severity caused by mutations (most often deletions or gene conversions) in the survival motor neuron (SMN1) gene. Molecular testing assesses the number of copies of the SMN1 gene. Individuals with one copy of the SMN1 gene are predicted to be carriers of SMA. Individuals with two or more copies have a reduced risk to be carriers. (Affected individuals have 0 copies of the SMN1 gene.)

This copy number analysis cannot detect individuals who are carriers of SMA as a result of either 2 (or very rarely 3) copies of the SMN1 gene on one chromosome and the absence of the SMN1 gene on the other chromosome or small intragenic mutations within the SMN1 gene. This analysis also will not detect germline mosaicism or mutations in genes other than SMN1. Additionally, de novo mutations have been reported in approximately 2% of SMA patients.

Carrier Frequency and Risk Reductions for Individuals with No Family History of SMA					
Ethnicity	Detection Rate ¹	A priori Carrier Risk ¹	Reduced Carrier Risk for 2 copy result	Reduced Carrier Risk for 3 copy result	
Caucasian	94.9%	1:35	1:632	1:3,500	
Ashkenazi Jewish	90.2%	1:41	1:350	1:4,000	
Asian	92.6%	1:53	1:628	1:5,000	
Hispanic	90.6%	1:117	1:1061	1:11,000	
African American	71.1%	1:66	1:121	1:3,000	
Mixed Ethnicities	For courseling surposes, consider using the ethnic background with the most conservative risk estimates.				

Mixed Ethnicities For counseling purposes, consider using the ethnic background with the most country of the second secon

METHOD/LIMITATIONS:

Specimen DNA is isolated and amplified by real-time polymerase chain reaction (PCR) for exon 7 of the SMN1 gene and two reference genes. A mathematical algorithm is used to calculate the number of copies of SMN1. Sequencing of the primer and probe binding sites for the SMN1 real-time PCR reaction is performed on all fetal samples, and on samples from individuals with 1 copy of SMN1 on carrier testing, to rule out the presence of sequence block with 1 copy of SMN1 on carrier testing. variants which could interfere with analysis and interpretation. False positive or negative results may occur for reasons that include genetic variants, blood transfusions, bone marrow transplantation, erroneous representation of family relationships or contamination of a fetal sample with maternal cells.

REFERENCES:

1. Carrier frequency and detection rate are calculated based on analysis of allele frequencies among > 1000 individuals from each ethnic group noted (Genzyme Genetics, data submitted for publication). 2. Online review of SMA: http://www.genereviews.org/profiles/sma

The test was developed and its performance characteristics have been determined by Genzyme. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test must be used in conjunction with clinical assessment, when available.

Electronically Signed by: Narasimhan Nagan, Ph.D., FACMG, on 09/18/2009

Reported by: /



Tay-Sachs Enzyme Analysis

Patient Name: D Referring Physic Specimen #: Patient ID:		#:			
DOB: Not Given SSN:	Date Collected: 06/17/20 Date Received: 06/19/20 Lab ID: 4157-100617 Hospital ID: Specimen Type: White B	10			
RESULTS: Hexosaminidase Activity : 2132 nmol/mg protein Hexosaminidase Percent A: 59.6					
			Plasma/Serum	WBC	
	Expected Non-Carrier Range:	Hex A	<u>≥</u> 55%	<u>></u> 55%	
	Expected Carrier Range:	Hex A	20 - 48%	20 - 49%	

INTERPRETATION: NON CARRIER

This result is within the non-carrier range for Tay-Sachs disease. Less than 0.1% of patients having non-carrier levels of Hexosaminidase-A activity are Tay-Sachs carriers.

NOTE: Maximum sensitivity and specificity for Tay-Sachs disease carrier testing are achieved by using enzymology and DNA mutation analysis together.



Under the direction of:

gel Warenberg, PHO, MOCC Stanford Marenberg, Ph.D.

Date: 06/29/2010 Page 1 of 1

Testing Performed At Genzyme Genetics 2000 Vivigen Way Santa Fe, NM 87505 1-800-848-4436

4978 Santa Anita Ave. Temple City, CA 91780 (p) 626-350-0537 (f) 626-454-1667 info@fulgentgenetics.com www.fulgentgenetics.com



Patient Information: 4157, Donor

Sex: M MR#: 4157 Patient#: Accession: Test#: Order#: Ext Test#: Ext Order#: Specimen Type: DNA Collected: Not provided Received Date: Mar 10,2023 Authorized Date: Mar 11,2023 Physician: Seitz, Suzanne ATTN: Seitz, Suzanne Fairfax Cryobank 3015 Williams Drive Fairfax, VA 22031 Phone: Fax: Laboratory: Fulgent Genetics CAP#: 8042697 CLIA#: 05D2043189 Laboratory Director: Dr. Hanlin (Harry) Gao Report Date: Mar 29,2023

Final Report

TEST PERFORMED

DHCR7 Single Gene

(1 Gene Panel: DHCR7; gene sequencing with deletion and duplication analysis)

RESULTS:

No clinically significant sequence or copy-number variants were identified in the submitted specimen.

A negative result does not rule out the possibility of a genetic predisposition nor does it rule out any pathogenic mutations of the sort not queried by this test or in areas not reliably assessed by this test.

INTERPRETATION:

Notes and Recommendations:

- As requested, this report only includes variants classified as Pathogenic, Likely Pathogenic, or Risk Allele at the time of analysis. If detected, this report does not include variants classified as of uncertain significance.
- Gene specific notes and limitations may be present. See below.
- These results should be interpreted in the context of this individual's clinical findings, biochemical profile, and family history.
- Genetic counseling is recommended. Available genetic counselors and additional resources can be found at the National Society of Genetic Counselors (NSGC; <u>https://www.nsgc.org</u>)
- Guide to Interpreting Genomic Reports: A Genomics Toolkit (CSER Consortium; February 2017) (<u>https://www.genome.gov/For-Health-Professionals/Provider-Genomics-Education-Resources#hep</u>)

GENES TESTED:

DHCR7 Single Gene 1 genes tested (100.00% at >20x).

DHCR7

Gene Specific Notes and Limitations

No gene specific limitations apply to the genes on the tested panel.

METHODS:

Patient: 4157, Donor; Sex: M; DOB: MR#: 4157

4978 Santa Anita Ave. Temple City, CA 91780 (p) 626-350-0537 (f) 626-454-1667 info@fulgentgenetics.com www.fulgentgenetics.com




Genomic DNA was isolated from the submitted specimen indicated above (if cellular material was submitted). DNA was barcoded, and enriched for the coding exons of targeted genes using hybrid capture technology. Prepared DNA libraries were then sequenced using a Next Generation Sequencing technology. Following alignment to the human genome reference sequence (assembly GRCh37), variants were detected in regions of at least 10x coverage. For this specimen, 100.00% and 100.00% of coding regions and splicing junctions of genes listed had been sequenced with coverage of at least 10x and 20x, respectively, by NGS or by Sanger sequencing. The remaining regions did not have 10x coverage, and were not evaluated. Variants were interpreted manually using locus specific databases, literature searches, and other molecular biological principles. To minimize false positive results, any variants that do not meet internal quality standards are confirmed by Sanger sequencing. Variants classified as pathogenic, likely pathogenic, or risk allele which are located in the coding regions and nearby intronic regions (+/- 20bp) of the genes listed above are reported. Variants outside these intervals may be reported but are typically not guaranteed. When a single pathogenic or likely pathogenic variant is identified in a clinically relevant gene with autosomal recessive inheritance, the laboratory will attempt to ensure 100% coverage of coding sequences either through NGS or Sanger sequencing technologies ("fill-in"). All genes listed were evaluated for large deletions and/or duplications. However, single exon deletions or duplications will not be detected in this assay, nor will copy number alterations in regions of genes with significant pseudogenes. Putative deletions or duplications identified by NGS are confirmed by an orthogonal method (gPCR or MLPA), unless exceeding an internally specified and validated quality score, beyond which deletions and duplications are considered real without further confirmation. New York patients: diagnostic findings are confirmed by Sanger, MLPA, or gPCR; exception SNV variants in genes for which confirmation of NGS results has been performed >=10 times may not be confirmed if identified with high guality by NGS. Bioinformatics: The Fulgent Germline v2019.2 pipeline was used to analyze this specimen.

LIMITATIONS:

These test results and variant interpretation are based on the proper identification of the submitted specimen, accuracy of any stated familial relationships, and use of the correct human reference sequences at the queried loci. In very rare instances, errors may result due to mix-up or co-mindling of specimens. Positive results do not imply that there are no other contributors, genetic or otherwise, to this individual's phenotype, and negative results do not rule out a genetic cause for the indication for testing. Official gene names change over time. Fulgent uses the most up to date gene names based on HUGO Gene Nomenclature Committee (https://www.genenames.org) recommendations. If the gene name on report does not match that of ordered gene, please contact the laboratory and details can be provided. Result interpretation is based on the available clinical and family history information for this individual, collected published information, and Alamut annotation available at the time of reporting. This assay is designed and validated for detection of germline variants only. It is not designed or validated for the detection of low-level mosaicism or somatic mutations. This assay will not detect certain types of genomic aberrations such as translocations, inversions, or repeat expansions (eg. trinucleotide or hexanucleotide repeat expansion). DNA alterations in regulatory regions or deep intronic regions (greater than 20bp from an exon) may not be detected by this test. Unless otherwise indicated, no additional assays have been performed to evaluate genetic changes in this specimen. There are technical limitations on the ability of DNA sequencing to detect small insertions and deletions. Our laboratory uses a sensitive detection algorithm, however these types of alterations are not detected as reliably as single nucleotide variants. Rarely, due to systematic chemical, computational, or human error, DNA variants may be missed. Although next generation sequencing technologies and our bioinformatics analysis significantly reduce the confounding contribution of pseudogene sequences or other highly-homologous sequences, sometimes these may still interfere with the technical ability of the assay to identify pathogenic alterations in both sequencing and deletion/duplication analyses. Deletion/duplication analysis can identify alterations of genomic regions which are two or more contiguous exons in size; single exon deletions or duplications may occasionally be identified, but are not routinely detected by this test. When novel DNA duplications are identified, it is not possible to discern the genomic location or orientation of the duplicated segment, hence the effect of the duplication cannot be predicted. Where deletions are detected, it is not always possible to determine whether the predicted product will remain in-frame or not. Unless otherwise indicated, deletion/duplication analysis has not been performed in regions that have been sequenced by Sanger.

SIGNATURE:

Yuan Xue, Ph.D., CGMB, FACMG on 3/29/2023 11:14 AM PDT Electronically signed



Accession#: FD Patient#: DocID:



PAGE 2 of 3





DISCLAIMER:

This test was developed and its performance characteristics determined by **Fulgent Genetics**. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. Since genetic variation, as well as systematic and technical factors, can affect the accuracy of testing, the results of testing should always be interpreted in the context of clinical and familial data. For assistance with interpretation of these results, healthcare professionals may contact us directly at (626) 350-0537 or info@fulgentgenetics.com. It is recommended that patients receive appropriate genetic counseling to explain the implications of the test result, including its residual risks, uncertainties and reproductive or medical options.